Citing preliminary financials, TG Therapeutics (NASDAQ:TGTX) announced Tuesday that the U.S. net sales from its multiple sclerosis therapy, Briumvi, for Q4 and full-year 2024 well exceeded its ...
NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), yesterday announced preliminary U.S. net product revenue for BRIUMVI ® for the fourth quarter and full year ended ...
empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements. For TG Therapeutics, the consensus EPS estimate for the quarter has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback